公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Performance Metrics for Selecting Single Nucleotide Polymorphisms in Late-onset Alzheimer's Disease | YEN-CHING CHEN ; Hsiao C.-J.; Jung C.-C.; Hu H.-H.; JEN-HAU CHEN ; Lee W.-C.; Chiou J.-M.; TA-FU CHEN ; Sun Y.; Wen L.-L.; Yip P.-K.; Chu Y.-M.; Chen C.-J.; Yang H.-I. | Scientific Reports | 16 | 8 | |
2014 | Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: A prospective study in Taiwan | CHI-LING CHEN ; WEI-SHIUNG YANG ; Yang H.-I.; Chen C.-F.; You S.-L.; Wang L.-Y.; Lu S.-N.; CHUN-JEN LIU ; JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN ; Chen C.-J. | Cancer Epidemiology Biomarkers and Prevention | 19 | 16 | |
2013 | Predicting clinical outcome in a patient with chronic hepatitis B virus infection | Yang H.-I.; PEI-JER CHEN | Clinical Liver Disease | 0 | 0 | |
2015 | Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system | Liu J.; TAI-CHUNG TSENG ; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; PEI-JER CHEN ; Chen C.-J.; JIA-HORNG KAO | Journal of Infectious Diseases | 16 | 13 | |
2013 | A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection | Liu J.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Iloeje U.H.; Lu S.-N.; Wang L.-Y.; You S.-L.; CHUHSING KATE HSIAO ; Yang H.-I.; Chen C.-J. | Journal of Hepatology | 81 | 69 | |
2013 | Preeclampsia and the Risk of Bronchopulmonary Dysplasia in VLBW Infants: A Population Based Study | TING-AN YEN ; Yang H.-I.; Hsieh W.-S.; HUNG-CHIEH CHOU ; CHIEN-YI CHEN ; Tsou K.-I.; PO-NIEN TSAO ; Hsu C.-H.; Mu S.-C.; Lin H.-C.; Huang C.-C.; Hsieh K.-S. | PLoS ONE | 52 | 44 | |
2013 | Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3 | PO-HAN LIN ; Lin C.-C.; Yang H.-I.; Li L.-Y.; Bai L.-Y.; Chiu C.-F.; Liao Y.-M.; Lin C.-Y.; Hsieh C.-Y.; Lin C.-Y.; Ho C.-M.; Yang S.-F.; Peng C.-T.; Tsai F.-J.; Yeh S.-P. | Leukemia Research | 34 | 31 | |
2022 | Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine | Park J.; Le A.K.; TAI-CHUNG TSENG ; Yeh M.-L.; Jun D.W.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung K.S.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO ; Yang H.-I.; Nguyen M.H. | Clinical Gastroenterology and Hepatology | 3 | 4 | |
2015 | R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability | Chen H.-Y.; SUNG-LIANG YU ; Ho B.-C.; KANG-YI SU ; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; CHONG-JEN YU ; KUAN-YU CHEN ; Tsai Y.-H.; Su W.-C.; HUEI-WEN CHEN ; Chen J.J.W.; Chen C.-J.; Chang G.-C.; PAN-CHYR YANG ; Li K.-C. | Journal of Clinical Oncology | 76 | 71 | |
2020 | Real-world effectiveness from the asia pacific rim liver consortium for hbv risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy | Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; TUNG-HUNG SU ; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; JIA-HORNG KAO ; Yuen M.-F.; Yu M.-L.; Nguyen M.H. | Journal of Infectious Diseases | 58 | 49 | |
2011 | Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score | Yang H.-I.; Yuen M.-F.; Chan H.L.Y.; Han K.-H.; PEI-JER CHEN ; Kim D.-Y.; Ahn S.-H.; Chen C.-J.; Wong V.W.S.; Seto W.-K. | The Lancet Oncology | 502 | 479 | |
2006 | Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level | Chen C.-J.; Yang H.-I.; Su J.; Jen C.-L.; You S.-L.; Lu S.-N.; GUAN-TARN HUANG ; Iloeje U.-H.; REVEAL-HBV Study Group | Journal of the American Medical Association | 2634 | 2370 | |
2015 | Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan | CHUN-JU CHIANG ; Yang Y.-W.; Chen J.-D.; You S.-L.; Yang H.-I.; Lee M.-H.; Lai M.-S.; Chen C.-J. | Hepatology | 86 | 76 | |
2014 | Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma | Liu J.; Yang H.-I.; Lee M.-H.; Lu S.-N.; Jen C.-L.; Batrla-Utermann R.; Wang L.-Y.; You S.-L.; CHUHSING KATE HSIAO ; PEI-JER CHEN ; Chen C.-J.; R.E.V.E.A.L.-HBV Study Group; (CHYI-FENG JAN) | Gut | 144 | 125 | |
2019 | Taiwan consensus statement on the management of chronic hepatitis B | Chien R.-N.; JIA-HORNG KAO ; Peng C.-Y.; Chen C.-H.; CHUN-JEN LIU ; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; YEN-HSUAN NI ; Chuang W.-L.; Lee C.-M.; Wu J.-C.; PEI-JER CHEN ; Liaw Y.-F. | Journal of the Formosan Medical Association | 50 | 47 | |
2019 | Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer | Peng H.-Y.; MING-CHU CHANG ; Hu C.-M.; Yang H.-I.; Lee W.-H.; YU-TING CHANG | Annals of Surgical Oncology | 18 | 21 | |
2021 | Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients | Liu M.; TAI-CHUNG TSENG ; Jun D.W.; Yeh M.-L.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung M.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO ; Yang H.-I.; Nguyen M.H. | Hepatology International | 14 | 14 |